These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 7045156)
1. Functional characteristics of a modified immunoglobulin preparation for intravenous administration: summary of studies of opsonic and protective activity against group B streptococci. Fischer GW; Wilson SR; Hunter KW J Clin Immunol; 1982 Apr; 2(2 Suppl):31S-35S. PubMed ID: 7045156 [TBL] [Abstract][Full Text] [Related]
2. Modified human immune serum globulin for intravenous administration: in vitro opsonic activity and in vivo protection against group B streptococcal disease in suckling rats. Fischer GW; Hunter KW; Wilson SR Acta Paediatr Scand; 1982 Jul; 71(4):639-44. PubMed ID: 6753478 [TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin therapy of neonatal group B streptococcal infections: an overview. Fischer GW Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S13-6. PubMed ID: 3041355 [TBL] [Abstract][Full Text] [Related]
4. Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models. Givner LB Pediatrics; 1990 Dec; 86(6):955-62. PubMed ID: 2123536 [TBL] [Abstract][Full Text] [Related]
5. Pooled human IgG hyperimmune for type III group B streptococci: evaluation against multiple strains in vitro and in experimental disease. Givner LB; Baker CJ J Infect Dis; 1991 May; 163(5):1141-5. PubMed ID: 2019763 [TBL] [Abstract][Full Text] [Related]
6. Type III group B streptococcal strain differences in susceptibility to opsonization with human serum. Fischer GW; Hunter KW; Wilson SR Pediatr Res; 1981 Dec; 15(12):1525-9. PubMed ID: 7033908 [TBL] [Abstract][Full Text] [Related]
7. Opsonic and protective activity of immunoglobulin, modified immunoglobulin, and serum against neonatal Escherichia coli K1 infection. Bortolussi R; Fischer GW Pediatr Res; 1986 Feb; 20(2):175-8. PubMed ID: 3511443 [TBL] [Abstract][Full Text] [Related]
8. Polyvalent group B streptococcal immune globulin for intravenous administration: overview. Fischer GW; Hemming VG; Gloser HP; Bachmayer H; von Pilar CE; Wilson SR; Baron PA Rev Infect Dis; 1990; 12 Suppl 4():S483-9; discussion S489-91. PubMed ID: 2194273 [TBL] [Abstract][Full Text] [Related]
9. The opsonic antibody response of female rats to type III group B streptococcal immunization: a model for maternal immunity. Heiman HS; Weisman LE Vet Immunol Immunopathol; 1990 Jan; 24(1):79-89. PubMed ID: 2180204 [TBL] [Abstract][Full Text] [Related]
10. Fibronectin enhances the opsonic and protective activity of monoclonal and polyclonal antibody against group B streptococci. Hill HR; Shigeoka AO; Augustine NH; Pritchard D; Lundblad JL; Schwartz RS J Exp Med; 1984 Jun; 159(6):1618-28. PubMed ID: 6374010 [TBL] [Abstract][Full Text] [Related]
11. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates. Weisman LE; Anthony BF; Hemming VG; Fischer GW J Pediatr; 1993 Jun; 122(6):929-37. PubMed ID: 8501574 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of bacterial opsonization by immune globulin intravenous: correlation of complement consumption with opsonic activity and protective efficacy. Yang KD; Bathras JM; Shigeoka AO; James J; Pincus SH; Hill HR J Infect Dis; 1989 Apr; 159(4):701-7. PubMed ID: 2494269 [TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin in the treatment of neonatal sepsis: therapeutic strategies and laboratory studies. Fischer GW; Hemming VG; Hunter KW; Gloser H; Bachmayer H; Von Pilar CE; Helting T; Weisman LE; Wilson SR; Baron PA Pediatr Infect Dis; 1986; 5(3 Suppl):S171-5. PubMed ID: 3520501 [TBL] [Abstract][Full Text] [Related]
14. A polyclonal human IgG preparation hyperimmune for type III, group B Streptococcus: in vitro opsonophagocytic activity and efficacy in experimental models. Givner LB; Edwards MS; Baker CJ J Infect Dis; 1988 Oct; 158(4):724-30. PubMed ID: 3049837 [TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease. Hill HR; Kelsey DK; Gonzales LA; Raff HV Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S87-91. PubMed ID: 1728992 [TBL] [Abstract][Full Text] [Related]
16. Functional activities of various preparations of human intravenous immunoglobulin against type III group B Streptococcus. Kim KS; Wass CA; Kang JH; Anthony BF J Infect Dis; 1986 Jun; 153(6):1092-7. PubMed ID: 3517187 [TBL] [Abstract][Full Text] [Related]
17. Directed immune globulin for the prevention or treatment of neonatal group B streptococcal infections: a review. Fischer GW; Weisman LE; Hemming VG Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S92-7. PubMed ID: 1728993 [TBL] [Abstract][Full Text] [Related]
18. Demonstration of opsonic and protective activity of human cord sera against type III group B streptococcus that are independent of type-specific antibody. Kim KS; Wass CA; Hong JK; Concepcion NF; Anthony BF Pediatr Res; 1988 Nov; 24(5):628-32. PubMed ID: 3060825 [TBL] [Abstract][Full Text] [Related]
19. Potential use of intravenous immune globulin for group B streptococcal infection. Baker CJ; Noya FJ Rev Infect Dis; 1990; 12 Suppl 4():S476-82. PubMed ID: 2194272 [TBL] [Abstract][Full Text] [Related]
20. Enhanced killing of group B streptococci in vitro by penicillin and opsonophagocytosis with intravenous immunoglobulin. Miller PS; Schauf V; Salo RJ J Infect Dis; 1990 Jun; 161(6):1225-30. PubMed ID: 2111840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]